Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Linaclotide Dose A Clear all
Completed Phase 2 Interventional Results available

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
77
States / cities
Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

NCT05760313
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 23 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically

NCT02220348
View directory record Official record
Conditions
Breast Feeding, Constipation, Irritable Bowel Syndrome
Interventions
linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

NCT04110145
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 7, 2026, 10:34 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Linaclotide for Colonoscopy Bowel Prep

NCT06692673
View directory record Official record
Conditions
Patients Scheduled for Colonoscopy
Interventions
Use of Linaclotide as a single agent Colonoscopy prep
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

NCT00402337
View directory record Official record
Conditions
Chronic Constipation
Interventions
linaclotide acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
60
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02559206
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
71
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

GCC Agonist Signal in the Small Intestine

NCT05107219
View directory record Official record
Conditions
Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
Interventions
Biopsy, Biospecimen Collection, Esophagogastroduodenoscopy, Linaclotide, Plecanatide
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Scottsdale, Arizona • Philadelphia, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 7, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT02559817
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
46
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570
View directory record Official record
Conditions
Functional Constipation in Children Ages 6-17 Years
Interventions
Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

NCT04026113
View directory record Official record
Conditions
Functional Constipation, Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
79
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT00765999
View directory record Official record
Conditions
Chronic Constipation, Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 7, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

NCT04166058
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Functional Constipation
Interventions
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 7, 2026, 10:34 PM EDT